HIV Real Talk: An educational webcast about HIV drug resistance www.HIVREALTALK.com   Ryan White Care Act Hepatitis C & B Language (click here for details)   Tibotec Announces Requests For Proposals for 2008 Global Developing World Initiatives More details on the 2008 REACH Initiative can be found on the www.tibotec.com web site   UCSF Anal Cancer Information Website: screening, treatment, and referral list of doctors in numerous cities (click here for details)   Current HIV Articles and News Updates     HIV     Guidelines Recommend Screening for Men at Increased Risk for Ostoeporosis. - (05/10/08)   Comparative Efficacy between therapies for bone disease: What We Know, What We Need to Know, and How We Can Get There EDITORIAL - (05/10/08)   Guidelines Recommend Screening for Men at Increased Risk for Ostoeporosis. "Screening for Osteoporosis in Men: A Clinical Practice Guideline from the American College of Physicians" - (05/10/08)   More HIV Articles...         News Updates     Las Vegas Health District Identifies 77 Potential Clinic Associated Infections - (05/08/08)   Is medical-marijuana use reason to deny someone a liver organ transplant? - (05/06/08)   Pharma Strategizes To Meet Future Challenges - (05/06/08)   Merck & BMS Continue Streamlining - (05/06/08)   More New Updates Articles...     Current Hepatitis C and B Articles     Hepatitis C     EASL: Locteron Viral Kinetics and Anti-Viral Activity during Treatment with a Controlled-Release Interferon Alfa-2b in Genotype 1 Chronic Hepatitis C Patients - (05/06/08)   EASL: POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR, R7128, IN COMBINATION WITH PEG-IFN a-2a AND RIBAVIRIN - (05/06/08)   EASL: High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin - (05/06/08)   EASL: RVR & Ribavirin Dose Predict SVR - (05/05/08)   More Hep C Articles...         Hepatitis B     EASL: Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with PEGASYS with or without lamivudine: results of 4-year follow-up: 11% HBsAg Clearance - (05/02/08)   More Hep B Articles...   Check Out Our Special NATAP Features   IAS Conference on HIV Pathogenesis, Treatment and Prevention   International Workshop on Hepatitis C, Resistance and New Compounds   International Workshop on Clinical Pharmacology of Hepatitis Therapy   ICAAC - Interscience Conference On Antimicrobial Agents & Chemotherapy (ICAAC)   International Symposium on Hepatitis C and Related Viruses   Infectious Diseases Society of America (IDSA)   Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)   International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV   European Conference on Clinical Aspects and Treatment of HIV-Infection (EACS)   Association Of Nurses In AIDS Care (ANAC)   International Workshop Targeting HIV Entry   National Viral Hepatitis Prevention Conference   International HIV and Hepatitis Co-infection Workshop   European HIV Drug Resistance Workshop   International Workshop on Clinical Pharmacology of HIV Therapy   International HIV Drug Resistance Workshop   International AIDS Conference   International Workshop on Clinical Pharmacology of HIV Therapy   International Workshop on Clinical Pharmacology of Hepatitis Therapy   Annual Meeting of the European Association for the Study of the Liver (EASL)   Digestive Disease Week   International HIV Drug Resistance Workshop   EASL: 43rd Annual Meeting of the European Association For The Study Of The Liver April 23-27, 2008 Milan, Italy   9th International Workshop on Clinical Pharmacology of HIV Therapy and The 3rd International Workshop on Clinical Pharmacology of Hepatitis Therapy 7-9 April 2008 New Orleans   6th European HIV Drug Resistance Workshop Budapest, Hungary March 26-28, 2008   15th CROI Conference on Retroviruses and Opportunistic Infections Boston, MA Feb 3-6, 2008   Targeting HIV Entry: 3rd International Workshop Washington, DC December 7-9, 2007   AASLD American Association For The Study of Liver Diseases Boston, MA November 2-6, 2007   11th European AIDS Conference Madrid October 24-27, 2007   IDSA Conference Infectious Disease Society San Diego, CA, Oct 7, 2007   View More Conference Reports...   New Goals and New Drugs for People With Heavy Anti-HIV Drug Experience - 06/05/07 Do you have HIV/HCV Coinfection? - 11/28/06 HIV 101 : The Basics - 11/28/06 VIH 101 : Lo Basico - in Spanish - 11/28/06 HIV 102 : Care and Treatment of HIV - 11/28/06 VIH 102 : Cuidado Y Tratamiento del VIH - in Spanish - 11/28/06 Hepatitis C and Hepatitis C Co-Infection Handbook PDF Version V 11/08/05 Download More NATAP Publications... Support provided by: Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Roche, Schering-Plough, Tibotec, Vertex   Patient Assistance Programs for HCV Therapy from the Drug Manufacturers: Pegylated Interferon and ribavirin If you cannot get reimbursement or coverage for pegylated interferon and ribavirin the manufacturers of pegylated interferon have reimbursement programs which supply free drugs if you qualify. These programs will first help you try to identify sources for reimbursement.   Schering makes Peg-Intron and ribavirin (Rebetol): Call 1-800-521-7157. Roche makes Pegasys and ribavirin (Copegus): 1-800-387-1258.